GSK still rid­ing vac­cine sales wave, push­ing 2024 fore­casts high­er

GSK’s vac­cines port­fo­lio is front and cen­ter as it kicks off 2024.

The UK phar­ma said its non-Covid vac­cine sales grew 22% in the first three months of the year to £2.27 bil­lion ($2.83 bil­lion) com­pared to the same pe­ri­od in 2023. This means its vac­cines fran­chise now ac­counts for around 30% of to­tal sales.

“We con­tin­ued to strength­en our in­no­v­a­tive vac­cine port­fo­lio this quar­ter,” CEO Em­ma Walm­s­ley said on a me­dia call. The com­pa­ny raised its 2024 op­er­at­ing prof­it growth guid­ance on Wednes­day from a pre­vi­ous range of 7% to 10%, to 9% to 11%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER